Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shane Shapera

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Current Oncology (Toronto, Ont.)|October 25, 2024
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint InhibitorsParneet K Cheema, Marco A J Iafolla, Husam Abdel-Qadir, et al.
Thorax|October 7, 2020
Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung diseaseAmy Po Yu Tsai, Seo Am Hur, Alyson Wong, et al.
Respirology (Carlton, Vic.)|March 4, 2024
Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi-centre registry cohortVeronica Marcoux, Stacey D Lok, Prosanta Mondal, et al.
Chest|February 29, 2024
The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung DiseaseSabina A Guler, Daniel-Costin Marinescu, Gerard Cox, et al.
Respiratory Research|July 9, 2021
Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung diseaseTao Chen, Amy Po Yu Tsai, Seo Am Hur, et al.
Respiratory Medicine|April 8, 2026
Impact of gastroesophageal reflux and proton pump inhibitors in fibrotic interstitial lung diseaseGiulia Nalesso, Giulia Ferranti, Daniel-Costin Marinescu, et al.
The European Respiratory Journal|March 1, 2023
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based studyYet H Khor, Max Schulte, Kerri A Johannson, et al.
Annals of the American Thoracic Society|December 13, 2021
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung DiseaseAlyson W Wong, Yet H Khor, Kathryn Donohoe, et al.
Respirology (Carlton, Vic.)|May 5, 2022
Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary FibrosisCathryn T Lee, Mary E Strek, Ayodeji Adegunsoye, et al.
Annals of the American Thoracic Society|September 7, 2023
Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung DiseaseFerhan Saleem, Christopher J Ryerson, Nandini Sarma, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Current Oncology (Toronto, Ont.)|October 25, 2024
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint InhibitorsParneet K Cheema, Marco A J Iafolla, Husam Abdel-Qadir, et al.
Thorax|October 7, 2020
Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung diseaseAmy Po Yu Tsai, Seo Am Hur, Alyson Wong, et al.
Respirology (Carlton, Vic.)|March 4, 2024
Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi-centre registry cohortVeronica Marcoux, Stacey D Lok, Prosanta Mondal, et al.
Chest|February 29, 2024
The Clinical Frailty Scale for Risk Stratification in Patients With Fibrotic Interstitial Lung DiseaseSabina A Guler, Daniel-Costin Marinescu, Gerard Cox, et al.
Respiratory Research|July 9, 2021
Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung diseaseTao Chen, Amy Po Yu Tsai, Seo Am Hur, et al.
Respiratory Medicine|April 8, 2026
Impact of gastroesophageal reflux and proton pump inhibitors in fibrotic interstitial lung diseaseGiulia Nalesso, Giulia Ferranti, Daniel-Costin Marinescu, et al.
The European Respiratory Journal|March 1, 2023
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based studyYet H Khor, Max Schulte, Kerri A Johannson, et al.
Annals of the American Thoracic Society|December 13, 2021
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung DiseaseAlyson W Wong, Yet H Khor, Kathryn Donohoe, et al.
Respirology (Carlton, Vic.)|May 5, 2022
Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the Canadian Registry for Pulmonary FibrosisCathryn T Lee, Mary E Strek, Ayodeji Adegunsoye, et al.
Annals of the American Thoracic Society|September 7, 2023
Predicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung DiseaseFerhan Saleem, Christopher J Ryerson, Nandini Sarma, et al.
Pageof 7